Rebecca Taub, M.D., is a distinguished medical professional who currently holds the position of President, Research & Development and Chief Medical Officer at Madrigal Pharmaceuticals, Inc. Dr. Taub has an extensive background in the pharmaceutical and biotechnology industries, with a focus on developing innovative treatments for metabolic and liver diseases. She joined Madrigal Pharmaceuticals in 2011 and has been instrumental in guiding the company's research and development efforts, particularly in the advancement of their lead drug candidate, resmetirom, for the treatment of non-alcoholic steatohepatitis (NASH). Prior to her role at Madrigal Pharmaceuticals, Dr. Taub held various leadership positions in the biopharmaceutical sector. She served as Senior Vice President and Global Chief Medical Officer at AstraZeneca, where she oversaw the development of several successful drug programs. Dr. Taub also worked at Bristol-Myers Squibb, where she led the clinical development of multiple compounds, including those for diabetes and cardiovascular diseases. Her academic credentials include an M.D. from the University of Pennsylvania School of Medicine and postdoctoral training at the Massachusetts Institute of Technology. As President, Research & Development and Chief Medical Officer at Madrigal Pharmaceuticals, Dr. Taub plays a pivotal role in shaping the company's scientific strategy and clinical development programs. Under her leadership, the company has made significant progress in advancing resmetirom through clinical trials, with promising results that have positioned Madrigal as a leader in the NASH treatment landscape. Dr. Taub's expertise and vision continue to drive the company's mission to develop transformative therapies for patients with serious liver and metabolic diseases.